The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition-Reference-Cited by-同舟云学术

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition

Published:2016-02-24 Issue:3 Volume:23 Page:329-342
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Aihara Tomohiko,Toyama Tatsuya,Takahashi Masato,Yamamoto Yutaka,Hara Fumikata,Akabane Hiromitsu,Fujisawa Tomomi,Ishikawa Takashi,Nagai Shigenori,Nakamura Rikiya,Tsurutani Junji,Ito Yoshinori,Mukai Hirofumi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12282-016-0670-y.pdf

Reference61 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized tirals. Lancet. 2011;378(9793):771–84.

2. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012;381(9869):805–16.

3. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46.

4. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.

5. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631–41.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study of lymphatic drainage patterns in patients undergoing SLNB with fluorescent dye using ICG in breast cancer patients—LYPIC;Breast Global Journal;2023

2. Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study;Japanese Journal of Clinical Oncology;2022-12-08

3. Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS);Cancer Science;2022-07-23

4. Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study;Japanese Journal of Clinical Oncology;2022-03-16

5. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond;Expert Opinion on Biological Therapy;2021-04-01